ViroPharma, Inc. (VPHM)

Major sell-off today for earnings that were actually somewhat close to what expected. For a recovering economy their earnings as near as it was is a good sign. Thanks for selling, now is the time to buy!

A undervalued biotech with a target price around $15

UL's rec

Short term holding till $13

I like their income statements, balance sheets......well I just like the company and at 5.5 P/E looks like a winner to me. $14 by years end methinks.

Making great profits and increasing them year to year, 5.55 P/E today, I like it

I had $2125 to invest today. I bought this. I'm glad I didn't miss the boat on this one; hate it when that happens...

I've been watching this stock for quite awhile and it finally hit my entry point. With this type of PE, for a biopharma, I see GOOD things, LONG term for this company.

insider buying

They will likely be bought.

This stock is poised for a sharp rise. They have over $3 per share in cash and are poised to take over another small company with Phase III data but may be short on cash, like they did with Lev. This would raise VPHM's cash flow behind the already substantial levels. Investors have not taken notice of the stock this year due to bad news in Feb. 2009 and subsequent second quarter writedown. They have some made some smart deals in the past year (Cinryze) essentially have a generic drug (Vancocin) that is selling and growing like it is still under patent protection due to a trade secret that continues to lock out the competition and should continue to do so. I am not too worried about competition from Optimer's fidaxomicin, nor anticipated generic vancomycin competition. I love situations like this and do not find that many of them. Buy under $11. I would recommend to VPHM management that they consider an outright purchase of a another small company, like NBIX.

.Viropharma was set back by the FDA and the publics over readtion to the news.Cinryze is still selling as before and this stock is a 5 * steal at 5.50.I see 15.00 in the not to distant future.

Considering Book value, earnings, and market cap...this should beat the market in 5 years.

Building a portfolio based on insider cluster buys.

watching this one, 5 stars, and a 10%+ insider just bought a lot of shares.

Long term.. Yup, definately long term.

Am I missing something? getting one of those too good to be true feelings...

fair value~~$19.07

Joel Greenblatt/Magic Formula pick, 4/21/09, coupled with high rating in CAPSshot (part of the MF Pro subscription)